Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pancreatitis is the most important complication of ERCP. The severity of this condition varies from mild to severe and can lead to prolonged hospitalization, surgical interventions, and even death. Several patient-related and procedure related factors have been identified that are associated with a higher risk of post-ERCP pancreatitis. So far, several methods have been proposed to avoid pancreatitis in patients at higher risk of this complication.

Several studies have shown that different drug therapies (indomethacin suppository, a sublingual nitrate tablet and the administration of intravenous Ringer's solution) each may reduce the incidence of post-ERCP pancreatitis. All these drug therapies are safe, cheap and easy to administer.

Several other studies have shown that pancreatic duct stenting (placement of a plastic tube in the pancreatic duct) is an effective intervention in preventing and reducing the severity of post-ERCP pancreatitis, especially in high-risk groups. However, there are still a few drawbacks to consider with pancreatic duct stenting: there are some difficulties with insertion of a PD stent, it is associated with a need for radiological follow-up and/or repeat endoscopy for removal, higher cost and a small but important risk of complications (e.g. stent migration).

Most of the clinical trials of pancreatic duct stenting were performed, before the results of trials of drug therapies were available. Moreover, no RCT (to the investigators knowledge) has compared the efficacy of pancreatic duct stenting in patients who already received a combination of drug therapies to prevent post-ERCP pancreatitis in high-risk patients. The purpose of this study is to determine the noninferiority of a combination of drug therapies in relation to pancreatic duct stenting to prevent post-ERCP pancreatitis in high-risk patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis

NCT06260878

Post-ERCP Acute Pancreatitis

RECRUITING PHASE4

Prophylaxis of Post-ERCP Acute Pancreatitis

NCT05381428

Pancreatitis, Acute

COMPLETED PHASE3

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

NCT03713879

Post ERCP Pancreatitis

RECRUITING PHASE3

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02641561

Post-ERCP Acute Pancreatitis

COMPLETED PHASE3

A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis

NCT02308891

Post-ERCP Acute Pancreatitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacological Prevention

Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting

Group Type PLACEBO_COMPARATOR

Indomethacin

Intervention Type DRUG

Indomethacin 100 mg suppository ten minutes before ERCP

Isosorbide Dinitrate

Intervention Type DRUG

Sublingual Isosorbide dinitrate 5 mg before ERCP

Ringer's lactate

Intervention Type DRUG

IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.

Pancreatic Stent

Pancreatic Stent PLUS Pharmacological Prevention

Group Type ACTIVE_COMPARATOR

Pancreatic Stent

Intervention Type DEVICE

A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting

Indomethacin

Intervention Type DRUG

Indomethacin 100 mg suppository ten minutes before ERCP

Isosorbide Dinitrate

Intervention Type DRUG

Sublingual Isosorbide dinitrate 5 mg before ERCP

Ringer's lactate

Intervention Type DRUG

IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pancreatic Stent

A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting

Intervention Type DEVICE

Indomethacin

Indomethacin 100 mg suppository ten minutes before ERCP

Intervention Type DRUG

Isosorbide Dinitrate

Sublingual Isosorbide dinitrate 5 mg before ERCP

Intervention Type DRUG

Ringer's lactate

IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients at high risk of post-ERCP Pancreatitis undergoing ERCP are eligible to enter the study. At least one major or two minor criteria must be present for the patient to be considered at high risk for PEP:

Major

* Sphincter of Oddi dysfunction.
* History of previous PEP.
* Pancreatic injection.
* Precut sphincterotomy.
* Balloon sphincter dilation without sphincterotomy.
* Pancreatic guidewire passages \> 1.

Minor

* Female patients aged\<60 years.
* Nondilated common bile duct (CBD).
* Normal serum bilirubin (\<2mg/dl).
* Failure to clear bile duct stones.
* Failed cannulation.
* Difficult cannulation (Time to CBD cannulation more than 10 min or more than five attempts at cannulation).

Exclusion Criteria

* Age younger than 15 years.
* History of sphincterotomy.
* Surgically altered anatomy (Billroth II gastrectomy or Roux-en-Y anastomosis).
* Uncontrolled coagulopathy.
* Tumor of ampulla of Vater.
* Those undergoing routine biliary-stent exchange.
* Acute pancreatitis at the time of ERCP.
* Chronic pancreatitis.
* Regular NSAID use during preceding week.
* Unable to tolerate indomethacin (Creatinine level \>1.4 mg/dL or active peptic ulcer disease).
* Unable to tolerate nitrates (closed-angle glaucoma).
* Unable to tolerate aggressive hydration (cardiac insufficiency: NYHA FC II or higher, renal insufficiency, electrolyte disturbances, clinical signs of fluid overload including peripheral or pulmonary edema, liver dysfunction with varix\>F1, or respiratory insufficiency).
* Patients requiring pancreatic duct drainage: to bridge dominant strictures, bypass obstructing pancreatic duct stones, drain pseudocysts, seal duct disruptions, pancreatic head cancer with main PD obstruction, IPMN or Pancreas divisum.
* Known main pancreatic duct stricture toward the head of pancreas.
* Pregnancy or breastfeeding.
* Refusal to participate in the study.

Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No